2023 AUA highlights in benign urology
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
In this episode of Speaking of Urology®, Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 American Urological Association Annual Meeting, which was held April 28-May 1 in Chicago, Illinois. Badlani is a Urology Times coeditor in chief and professor and vice chair of urology at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and Dr. Kaplan is a professor of Urology and a director of the men’s wellness program at the Icahn School of Medicine at Mount Sinai in New York.
During their discussion, they touched on the following topics:
- The Innovation Nexus
- PD41-03: 12-Month Outcomes from a Randomized, Sham Controlled Study Evaluating a Novel Drug Coated Balloon for the Treatment of BPH
- PD41-02: 12-Month Outcomes from the first North American study of the Zenflow Spring System for the Treatment of Benign Prostatic Hyperplasia (BPH)
- LBA01-05: Pivotal Study of a Novel Wirelessly Powered, Patient Tailored Programmed, Tibial Neurostimulator for the Treatment of Patients with Overactive Bladder
- LBA01-12: Platelet Rich Plasma for the Treatment of Erectile dysfunction: A Prospective, Randomized, Double Blind, Placebo Controlled Clinical Trial
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
